Zobrazeno 1 - 10
of 267
pro vyhledávání: '"59"'
Autor:
Danni Yu, Ute Hoch, Sara M. Tolaney, Adi Diab, Arika Feils, Arlene O. Siefker-Radtke, KyungMann Kim, Jen Birstler, Paul M. Sondel, Sue Currie, Tuan Nguyen, Amy K. Erbe, Matthew D. Hellmann, Nizar M. Tannir
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A67-A67
BackgroundHigh-dose IL2 therapy has shown clinical benefit in metastatic melanoma and renal cell carcinoma, however only in a select subset of patients. Bempegaldesleukin (BEMPEG), a novel CD122-preferential IL2 pathway agonist, preferentially binds
Publikováno v:
Journal of Clinical Oncology. 24:7583-7583
7583 Background: The introduction of HAART has significantly improved the outcome of pts with HD-HIV. However there are no data on the long-term follow-up of HD-HIV pts treated with conventional chemotherapy (CT) regimens and concomitant HAART. In 20
Autor:
A. Roth, S. HsuSchmitz, Ralph A. Schmid, M. Pless, Anastase Spiliopoulos, Rolf A. Stahel, Hans B. Ris, Daniel C. Betticher, W. Weder, Thomas Cerny
Publikováno v:
Lung Cancer. 49:S14
Autor:
Ju Hyun Lee, Jin Won Kim, Koung Jin Suh, Yu Jung Kim, Ki Hwan Kim, Jin Soo Kim, Jee Hyun Kim, Jin Hyun Park, In Sil Choi, Ji Won Kim
Publikováno v:
European journal of cancer (Oxford, England : 1990). 154
Background In locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin. This study evaluated whether irinotecan/5-fluorouracil (5-FU; mFOLFIRI) was supe
Autor:
Ruey-Long Hong, Jia-Hong Chen, Ching Yun Hsieh, Li Yuan Bai, Chen Yuan Lin, Ming-Yu Lien, Mu-Hsin Chang, Shang-Hung Chen, Ren-Hua Ye, Muh Hwa Yang, Nai-Jung Chiang, Shang-Yin Wu, Chin-Fu Hsiao, Hsiang-Fong Kao, Li-Tzong Chen, Tsang Wu Liu
Publikováno v:
Journal of Clinical Oncology. 39:6025-6025
6025 Background: Liposomal irinotecan (nal-IRI) + 5-FU/LV has been approved and used in treating patients with metastatic pancreatic cancer after gemcitabine-based therapy through the NAPOLI-1 study result. This phase 2 trial evaluated the activity o
Autor:
Jie Wang, Haihua Yang, Yanjun Xu, Yi Hu, Xingya Li, Dingzhi Huang, Wang Lifeng, Xiaoyan Lin, Jianhua Chen, Jun Zhao, Yun Fan, Yanping Hu, Caicun Zhou, Jianying Zhou, Hanying Li, Yong Fang, Qiming Wang, Zhijie Wang
Publikováno v:
Cancer Research. 80:CT083-CT083
Background: Treatment options in 2nd-line extensive-stage small-cell lung cancer (ED-SCLC) setting are very limited. PASSION (NCT03417895) was a phase 2 study of camrelizumab plus apatinib in ED-SCLC after platinum-based chemotherapy. Methods: In the
Autor:
Anna Maria Storniolo, Aditya Bardia, Cesar A. Santa-Maria, Vered Stearns, Claire F. Snyder, Antonio C. Wolff, Stacie Jeter, Anne Nguyen, Shannon Slater, Daniel F. Hayes, John H. Fetting, Katie Quinlan, Robert S. Miller, Roisin M. Connolly, Nora Lynn Henry, Gary L. Rosner, Jane Zorzi, Amanda L. Blackford
Publikováno v:
Breast cancer research and treatment. 171(1)
PURPOSE: Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are common adverse events of AIs often leading to drug discontinuation. We initiated a prospective clinical trial to evaluate whether bisphosphonates are associated with reduced
Autor:
Axel Wein, Juergen Siebler, Dagmar Busse, Markus F. Neurath, Kirsten Merx, Kerstin Wolff, Nicola Ostermeier, Franz Koch, Alexander F. Hagel, Ralf-Dieter Hofheinz
Publikováno v:
Anticancer research. 37(7)
Background/aim The aim of this work was to evaluate the efficacy and safety of second-line treatment with weekly high-dose 5-fluorouracil (5-FU) as a 24-hour infusion (24-h inf.) combined with sodium folinic acid (FA) (AIO-regimen) plus irinotecan (I
Autor:
J. Benk, A. Niestroy, Lutz Edler, E. Laack, J Scholtze, Heinz Dürk, C. Lorenz, T Walter, A. Chemaissani, T. Mende, D.K. Hossfeld, K. Dalhoff, T Müller
Publikováno v:
European Journal of Cancer. 37:583-590
The purpose of this phase II study was to investigate the efficacy and safety of gemcitabine plus vinorelbine as first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Eligibility criteria included cytologically or hist
Autor:
Ghazaleh Tabatabai, Peter Lewandrowski, Monika Stieglbauer, Stefan Stevanovic, Sandra Heesch, Per thor Straten, Jordi Rodon, Ugur Sahin, Juan Sahuquillo, Colette Song, Valérie Dutoit, Randi Kristina Feist, Christian H. Ottensmeier, Francisco Martínez-Ricarte, Sabrina Kuttruff-Coqui, Hideho Okada, Bernhard Rössler, Judith R. Kroep, Wick Wolfgang, Jens Fritsche, Regina Mendryzk, Norbert Hilf, Karoline Laske, Hans-Georg Rammensee, Carsten Reinhardt, Marij Schoenmaekers-Welters, Harpreet Singh-Jasuja, Stevermann Lea, Toni Weinschenk, Michael Platten, Sjoerd H. van der Burg, Marco Skardelly, Katrin Frenzel, Ulrik Lassen, Christoph Huber, Valesca Bukur, Arie Admon, Berta Ponsati, David Capper, Hans Skovgaard Poulsen, Pierre-Yves Dietrich, Miriam Meyer, Anna Paruzynski, Nina Pawlowski, Sebastian Kreiter, Cécile Gouttefangeas, Andreas von Deimling, Martin Löwer, Jordi Piro
Publikováno v:
Cancer Research. 76:2654-2654
The Glioma Actively Personalized Vaccine Consortium (GAPVAC; funded by the European Union Framework 7 Program) aims at treating newly diagnosed glioblastoma (GB) patients with two distinct actively personalized vaccines (APVACs). Resected tumor mater